Karyopharm Therapeutics
KPTI
90 hedge funds and large institutions have $298M invested in Karyopharm Therapeutics in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 5 closing their positions.
393% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $242K
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
17% more funds holding
Funds holding: 77 → 90 (+13)
0.32% more ownership
Funds ownership: 4.06% → 4.38% (+0.32%)
6% less capital invested
Capital invested by funds: $316M → $298M (-$17.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$2.14M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$803K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$735K |
| 5 |
Millennium Management
New York
|
+$706K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$8.1M |
| 2 |
BlackRock
New York
|
-$4.32M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.63M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$1.16M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.15M |
KPTI Hedge Fund Activity: Q4 2017 in Review
90 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2017, worth a combined $298M — down 5.7% from $316M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KPTI positions and 5 closed out — a net gain of 13 holders — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $35.9M. The largest seller was Tekla Capital Management, cutting an estimated $8.1M.
- 90 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2017, up from 77 in Q3 2017.
- Funds reported $298M of Karyopharm Therapeutics stock for Q4 2017, down 5.7% quarter-over-quarter.
- 18 funds opened new Karyopharm Therapeutics positions in Q4 2017 and 5 closed out, a net change of +13 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2017 was Point72 Asset Management, an estimated $35.9M added.
- The largest Karyopharm Therapeutics seller in Q4 2017 was Tekla Capital Management, an estimated $8.1M sold.
Based on aggregated 13F filings for Q4 2017.